Motavizumab
Motavizumab is an anti-RSV humanized IgG1 MAb that was derived by affinity maturation of palivizumab (Synagis ®) and is 10-20 times more potent than palivizumab at neutralizing RSV in tissue culture. A Biologic License Application (BLA) for motavizumab was submitted to the FDA in January 2008 and accepted for filing in March 2008.